Table 2.
Summary of findings and strength of evidence in studies
| Outcome | No. of patients (Trials) | RR/MD (95% CI) | I2 | Absolute effect estimates (per 1000) | Quality of the evidence | ||
|---|---|---|---|---|---|---|---|
| Intervention | Control | Difference | |||||
| Cardiovascular events | 3008 (2) | 0.75 [0.56, 0.99] | 0% | 56 | 74 | − 19 [− 1, − 33] | High |
| Percent change of LDL-C | 3957 (9) | − 22.91 [− 27.35, − 18.47] | 99% | – | – | – | Moderate# |
| New-onset or worsening diabetes | 3621 (4) | 0.65 [0.44, 0.96] | 23% | 38 | 58 | − 20 [− 2, − 32] | Moderate§ |
| Percent change of CRP | 3555 (7) | − 24.70 [− 32.10, − 17.30] | 53% | – | – | – | Moderate# |
| Myocardial infarction | 3008 (2) | 0.54 [0.25, 1.15] | 37% | 12 | 22 | − 10 [− 17, 3] | Moderate§,# |
| Coronary revascularization | 3008 (2) | 0.74 [0.50, 1.10] | 0% | 29 | 39 | − 10 [− 20, 4] | Moderate§ |
| Cardiovascular death | 3008 (2) | 1.65 [0.46, 5.98] | 0% | 5 | 3 | 2 [− 2, 15] | Moderate§ |
| Nonfatal stroke | 3008 (2) | 1.11 [0.34, 3.61] | 0% | 4 | 4 | 0 [− 3, 10] | Moderate§ |
| Hospitalization for unstable angina | 2574 (2) | 0.84 [0.41, 1.73] | 51% | 11 | 13 | − 2[− 8, 9] | Low#,§ |
| Any adverse event | 4188 (9) | 1.01 [0.97, 1.05] | 40% | 712 | 705 | 7 [− 21, 35] | Low&,# |
| Serious adverse event | 4184 (9) | 1.06 [0.89, 1.26] | 0% | 126 | 119 | 7 [− 13, 31] | Moderate& |
| Muscular-related adverse event | 2703 (3) | 1.12 [0.80, 1.56] | 26% | 120 | 107 | 13 [− 21, 60] | Moderate§ |
| Decrease in glomerular filtration rate | 3276 (3) | 3.61 [0.81, 16.04] | 0% | 4 | 1 | 3 [− 1, 14] | Low* |
| Increase in blood creatinine | 3482 (4) | 2.15[0.81, 5.69] | 0% | 6 | 3 | 3 [− 1, 16] | Moderate§ |
| Increase in blood uric acid | 1176 (3) | 3.76 [1.24, 11.39] | 0% | 30 | 8 | 22 [2,81] | Low* |
| Gout | 3421 (4) | 2.37 [0.88, 6.36] | 12% | 12 | 5 | 7 [− 1, 43] | Moderate§ |
| Neurocognitive disorders | 3076 (3) | 0.94 [0.41, 2.17] | 0% | 8 | 8 | 0 [− 5, 9] | Moderate§ |
| ALT or AST > 3 × ULN | 3382 (5) | 1.97 [0.61, 6.34] | 0% | 6 | 3 | 3 [− 1, 14] | Moderate§ |
| CK > 5 × ULN | 3382 (5) | 1.31 [0.23, 7.50] | 19% | 3 | 2 | 1 [− 1, 12] | Moderate§ |
LDL-C Low density lipoprotein cholesterol, CRP C-reactive protein, CK Creatine kinase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit of the normal range, RR Risk ratio, MD Mean difference
&Publication bias
#Inconsistency
§Imprecision
*Very serious imprecision